Baillie Gifford & Co
REGN icon

Baillie Gifford & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Baillie Gifford & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-54
Closed -$44.4K – 411
2023
Q1 		$44.4K Buy
54
+7
+15% +$5.28K ﹤0.01% 292
2022
Q4 		$33.9K Hold
47
– – ﹤0.01% 310
2022
Q3 		$32K Sell
47
-3
-6% -$1.89K ﹤0.01% 304
2022
Q2 		$30K Buy
50
+4
+9% +$2.6K ﹤0.01% 310
2022
Q1 		$32K Hold
46
– – ﹤0.01% 313
2021
Q4 		$29K Sell
46
-9
-16% -$5.53K ﹤0.01% 334
2021
Q3 		$33K Sell
55
-8
-13% -$4.97K ﹤0.01% 311
2021
Q2 		$35K Hold
63
– – ﹤0.01% 307
2021
Q1 		$30K Buy
63
+3
+5% +$1.46K ﹤0.01% 301
2020
Q4 		$29K Buy
+60
New +$32.4K ﹤0.01% 296
2018
Q2 		– Sell
-5,500
Closed -$1.89M – 209
2018
Q1 		$1.89M Hold
5,500
– – ﹤0.01% 198
2017
Q4 		$2.07M Hold
5,500
– – ﹤0.01% 192
2017
Q3 		$2.46M Hold
5,500
– – ﹤0.01% 190
2017
Q2 		$2.7M Hold
5,500
– – ﹤0.01% 190
2017
Q1 		$2.13M Hold
5,500
– – ﹤0.01% 187
2016
Q4 		$2.02M Sell
5,500
-4,600
-46% -$1.75M ﹤0.01% 194
2016
Q3 		$4.06M Hold
10,100
– – 0.01% 182
2016
Q2 		$3.53M Hold
10,100
– – 0.01% 179
2016
Q1 		$3.64M Sell
10,100
-2,600
-20% -$1.07M 0.01% 180
2015
Q4 		$6.89M Sell
12,700
-7,900
-38% -$4.28M 0.01% 154
2015
Q3 		$9.58M Hold
20,600
– – 0.02% 150
2015
Q2 		$10.5M Hold
20,600
– – 0.02% 144
2015
Q1 		$9.3M Hold
20,600
– – 0.02% 153
2014
Q4 		$8.45M Hold
20,600
– – 0.02% 156
2014
Q3 		$7.43M Sell
20,600
-16,180
-44% -$5.42M 0.02% 160
2014
Q2 		$10.4M Hold
36,780
– – 0.02% 152
2014
Q1 		$11M Hold
36,780
– – 0.03% 143
2013
Q4 		$10.1M Sell
36,780
-2,672
-7% -$769K 0.02% 141
2013
Q3 		$12.3M Buy
39,452
+37,780
+2,260% +$9.94M 0.03% 130
2013
Q2 		$376K Buy
+1,672
New +$389K ﹤0.01% 152

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co's REGN Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 54 shares — an estimated $44.4K sold.

Baillie Gifford & Co first reported a position in REGN in Q2 2013 and held it in 30 quarters. The position peaked at $12.3M in Q3 2013. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 54 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $44.4K.
  • Baillie Gifford & Co first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • Baillie Gifford & Co's Regeneron Pharmaceuticals position peaked at $12.3M in Q3 2013.
  • 1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.